These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6973302)

  • 1. Risk factors for obstructive lung disease.
    Madison R; Mittman C; Afifi AA; Zelman R
    Am Rev Respir Dis; 1981 Aug; 124(2):149-53. PubMed ID: 6973302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ.
    Seersholm N; Wilcke JT; Kok-Jensen A; Dirksen A
    Am J Respir Crit Care Med; 2000 Jan; 161(1):81-4. PubMed ID: 10619801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of smoking and intermediate alpha 1-antitrypsin deficiency (PiMZ) on lung function.
    Eriksson S; Lindell SE; Wiberg R
    Eur J Respir Dis; 1985 Oct; 67(4):279-85. PubMed ID: 3878302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors, pulmonary function, and mortality.
    Menkes HA; Cohen BH; Beaty TH; Newill CA; Khoury MJ
    Prog Clin Biol Res; 1984; 147():501-21. PubMed ID: 6610878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collaborative study to assess risk of lung disease in Pi MZ phenotype subjects.
    Bruce RM; Cohen BH; Diamond EL; Fallat RJ; Knudson RJ; Lebowitz MD; Mittman C; Patterson CD; Tockman MS
    Am Rev Respir Dis; 1984 Sep; 130(3):386-90. PubMed ID: 6332562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group.
    Turino GM; Barker AF; Brantly ML; Cohen AB; Connelly RP; Crystal RG; Eden E; Schluchter MD; Stoller JK
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1718-25. PubMed ID: 8970361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of neutrophil elastase, serum trypsin inhibitory activity, and smoking history as risk factors for chronic obstructive pulmonary disease in patients with MM, MZ, and ZZ phenotypes for alpha-antitrypsin.
    Galdston M; Melnick EL; Goldring RM; Levytska V; Curasi CA; Davis AL
    Am Rev Respir Dis; 1977 Nov; 116(5):837-46. PubMed ID: 303486
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis.
    Silverman EK; Chapman HA; Drazen JM; Weiss ST; Rosner B; Campbell EJ; O'DONNELL WJ; Reilly JJ; Ginns L; Mentzer S; Wain J; Speizer FE
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1770-8. PubMed ID: 9620904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, epidemiologic, and pulmonary function studies in alpha,-antitrypsin-deficient subjects of Pi Z type.
    Rawlings W; Kreiss P; Levy D; Cohen B; Menkes H; Brashears S; Permutt S
    Am Rev Respir Dis; 1976 Nov; 114(5):945-53. PubMed ID: 1086622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrelationships between serum chemotactic factor inactivator, alpha 1-antitrypsin deficiency, and chronic obstructive lung disease.
    Lam S; Chan-Yeung M; Abboud R; Kreutzer D
    Am Rev Respir Dis; 1980 Mar; 121(3):507-12. PubMed ID: 6968167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic obstructive pulmonary disease and alpha-1-antitrypsin (Pi) variation: a family study.
    Benjamin JJ; Cohen BH; Ball WC; Levy DA; Menkes HA; Kreiss P
    Birth Defects Orig Artic Ser; 1974; 10(4):212-6. PubMed ID: 4549777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host factors in chronic obstructive pulmonary disease in an upper Midwest rural community. Design, case selection, and clinical characteristics in a matched-pair study.
    Miller RD; Hepper NG; Kueppers F; Gordon H; Offord KP
    Mayo Clin Proc; 1976 Nov; 51(11):709-15. PubMed ID: 1086934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PiMZ phenotype: is it a significant risk factor for the development of chronic obstructive lung disease?
    Mittman C
    Am Rev Respir Dis; 1978 Oct; 118(4):649-52. PubMed ID: 309294
    [No Abstract]   [Full Text] [Related]  

  • 14. A longitudinal study of alpha1-antitrypsin phenotypes and decline in FEV1 in a community population.
    Silva GE; Sherrill DL; Guerra S; Barbee RA
    Chest; 2003 May; 123(5):1435-40. PubMed ID: 12740258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of alpha-antitrypsin heterozygotes (Pi MZ) in patients with obstructive pulmonary disease.
    Shigeoka JW; Hall WJ; Hyde RW; Schwartz RH; Mudholkar GS; Speers DM; Lin CC
    Am Rev Respir Dis; 1976 Dec; 114(6):1077-84. PubMed ID: 1087539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of chronic obstructive pulmonary disease in patients with intermediate levels of alpha-antitrypsin.
    Klayton R; Fallat R; Cohen AB
    Am Rev Respir Dis; 1975 Jul; 112(1):71-5. PubMed ID: 238443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological studies in a large sibship with antitrypsin deficiency.
    Duncan PE; Griffin JP
    Br J Dis Chest; 1975 Apr; 69(2):107-17. PubMed ID: 49190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal lung function study in heterozygous PiMZ phenotype subjects.
    Tarján E; Magyar P; Váczi Z; Lantos A; Vaszár L
    Eur Respir J; 1994 Dec; 7(12):2199-204. PubMed ID: 7713204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha 1-antitrypsin phenotypes and obstructive lung disease in the city of Oslo.
    Gulsvik A; Fagerhol MK
    Scand J Respir Dis; 1979 Oct; 60(5):267-74. PubMed ID: 316573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease inhibitors in chronic obstructive pulmonary disease.
    Barnett TB; Gottovi D; Johnson AM
    Am Rev Respir Dis; 1975 May; 111(5):587-93. PubMed ID: 1079422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.